Evangeline A. Reyes, MD
CAREER MISSION STATEMENT
To provide quality healthcare to cancer patients comprised of compassion, dedication, and honesty. To maintain knowledge in and to provide patients with the most up-to-date medical care available.
PROFESSIONAL EXPERIENCE
2002 – present Hematologist/Oncologist
Compassionate Cancer Care Medical Group, Inc.
11180 Warner Avenue, Suite 365, Fountain Valley, California 92708
260 E. Ontario Avenue, Suite 101, Corona, California 92879
4500 Brockton Avenue, Suite 107, Riverside, CA 92501
2001 – 2002 Hematologist/Oncologist
Pacific Coast Hematology/Oncology Medical Group, Inc.
Fountain Valley, California
2000 – 2001 Hematologist/Oncologist
Inland Hematology-Oncology Medical Group, Inc.
San Bernardino, California
1997 – 1999 Hematologist/Oncologist
Blair Medical Associates/Altoona Hospital
Altoona, Pennsylvania
LEADERSHIP POSITIONS
1997 – 1999 Chair, Clinical Protocols, Blair Medical Associates/Altoona Hospital
Altoona, Pennsylvania
1998 – 1999 Vice Chair, Altoona Hospital Institutional Review Board
Altoona, Pennsylvania
1998 – 1999 Instructor: Hematology/Oncology, Allegheny Family Residency Program
Allegheny, Pennsylvania
HOSPITAL AFFILIATION APPOINTMENTS
Fountain Valley Regional Hospital & Medical Center, Fountain Valley, California
Corona Regional Medical Center, Corona, California
Orange Coast Memorial Hospital, Fountain Valley, California
EDUCATION
June 1984 – April 1988 Medical Degree
University of the East Ramon Magsaysay
Ramon Magsaysay Memorial Medical Center,
Quezon City, Philippines
June 1980 – May 1984 B.S. in Zoology (pre-med)
University of the East, Manila, Philippines
RESIDENCY
July 1991 – June 1994 Internship and Residency
Berkshire Medical Center
Affiliate of University of Massachusetts, Pittsfield, Massachusetts
FELLOWSHIPS
July 1994 – June 1997 Fellow, Hematology/Oncology
Medical College of Virginia, Richmond, Virginia
BOARD CERTIFICATION
Diplomate, Medical Oncology, November 1999
Board Eligible, Hematology, July 1997
Diplomate, American Board of Internal Medicine, August 1996
FLEX, June 1991
FMGEM, Part II, July 1990
FMGEM, Part I, January 1990
LICENSURE
Virginia License #053406
Pennsylvania License #063189
California License #A64361
Florida License #77813
RESEARCH AFFILIATIONS
Member of National Surgical Adjuvant Breast and Bowel Project (NSABP)
MEMBERSHIPS
American Society of Clinical Oncology
American College of Physicians
American Society of Internal Medicine
Massachusetts Medical Society
BIOGRAPHICAL DATA
Date of Birth: January 7, 1962
Citizenship: USA
CLINICAL RESEARCH ACTIVITY
BLADDER CANCER
Interleukin 2 in an Alternative Dose: Treatment of Patients with Metastatic Renal Cell Cancer with Low Dose Proleukin
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
BREAST CANCER
Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd Line Patients
Principal Investigator: Glen R. Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects with Advanced Breast Cancer Treated with Single Agent Docetaxel
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Multicenter Phase III Randomized Trial Comparing Docetaxel In Combination With Doxorubicin And Cyclophosphamide (TAC) Versus Doxorubicin And Cyclophosphamide Followed By Docetaxel (AC⇐T) As Adjuvant Treatment Of Operable Breast Cancer HER2NEU Negative Patients With Positive Axillary Lymph Nodes
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
BREAST CANCER CONTINUED
A Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC⇐T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC⇐TH) and with Docetaxel, Platinum Salt and Trastuzumab (TCH) in th Adjuvant Treatment of Node Positive and High Risk Node Negative Patients with Operable Breast Cancer Containing the HER2NEU Alteration
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere®) and Trastuzumab (Herceptin®) with Docetaxel (Taxotere®), Carboplatin, and Trastuzumab (Herceptin®) as First line Chemotherapy for Patients with Advanced Breast Cancer Containing the HER2Gene Amplification
Principal Investigator: Glen R. Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
Phase III Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Vs Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer
Principal Investigator: Glen R. Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
Breast Cancer Siblings Database
Principal Investigator: Glen R. Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
Clinical Outcomes in Patients with HER2 Gene-Amplified Metastatic Breast Cancer Treated with First-Line Herceptin® in Combination with a Taxane: A Phase IV, Prospective, Community-Based Study
Principal Investigator: Glen R. Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
The Traviota Study: Trastuzumab (Herceptin®) and Either Vinorelbine (Navelbine®) or Taxane-Based Chemotherapy in Patients with HER2 Overexpressing Metastatic Breast Cancer: A Randomized Phase III Study
Principal Investigator: Glen R. Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
Open-Label Study of Femara (2.5 mg) Daily for Patients with ER Receptor Positive Advanced Breast Cancer.
Principal Investigator: Glen R. Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
BREAST CANCER CONTINUED
A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capcitabine (Xeloda®) Tablets Twice Daily For 2 Weeks in 3-week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline therapy.
Principal Investigator: Evangeline Reyes, M.D.
A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of fulvestrant (FASLODEX™) vs. exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer with Disease Progression after Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
COLORECTAL CANCER
A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination with Standard Chemotherapy in Subjects with Metastatic Colorectal Cancer; Second-line Treatment of rhuMAb VEGF with or without Chemotherapy for Subjects whose Cancer Progressed on the Protocol
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
An Open-Label, Single-Arm Trial of Patients with Metastatic Colorectal Cancer Receiving Irinotecan, 5-Fluorouracil, and Leucovorin Followed by Leukine® (Sargramostim), a Recombinant Human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
An Open-Label Phase II Study of Intermittent Oral Capecitabine in Combination with Intravenous Irinotecan (Q3W) in Patients with Advanced and/or Metastatic Colorectal Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangline Reyes, M.D.
A Compassionate Use Study of Oxaliplatin in the Treatment of Metastatic Colorectal Carcinoma
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
COLORECTAL CANCER CONTINUED
An Open-Label, Single-Arm Trial of Patients with Metastatic Colorectal Cancer Receiving Irinotecan, 5-Fluorouracil, and Leucovorin Followed by Leukine, a Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Treatment Access Program with Oxaliplatin for Previously Treated Colorectal Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
An Open-Label Randomized Phase III Study Comparing Xeloda with IV Bolus 5-FU in Combination with Low Dose Leucovorin as Adjuvant Chemotherapy in Patients who Underwent Surgery for Dukes C Colon Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
GASTRIC CANCER
Open Label, Randomized Multicenter Phase II/III Study of Docetaxel in Combination with Cisplatin (CDDP) or Docetaxel in Combination with 5-FU and CDDP Compared to the Combination of CDDP and 5-FU in Patients with Metastatic or Locally Recurrent Gastric Cancer Previously Untreated with Chemotherapy for Advanced Disease.
Principal Investigator: Lalita Pandit, M.D./ Glen R. Justice, MD
Sub-Investigator: Evangeline Reyes, M.D.
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients with Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
HEMATOLOGIC MALIGNANCIES
A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared with Rituxan Alone in Patients with Relapsed or Refractory Follicular Non-Hodgkin’s Lymphoma
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
HEMATOLOGIC MALIGNANCIES CONTINUED
A Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Rituxan (Rituximab) in Combination with Six Cycles of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) Followed by Rituxan Maintenance as Initial Therapy for Patients with Advanced Stage Indolent Non-Hodgkin’s Lymphoma
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
LUNG CANCER
An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent. Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients With Small Cell Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
Evaluation of Docetaxel and Cisplatin With Filgrastim Support for the Treatment of Patients With Stage III or IV Non-small Cell Lung Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Phase III Trial of Alimta versus Docetaxel in Patients Previously Treated with One Chemotherapy Regimen for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere in Combination with Aptosyn versus Taxotere and Placebo in NSCLC Patients after Failure of Prior Platinum-Based Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
An Open-Label, Multicenter, Randomized Phase III Study of Hycamtin Topotecan) as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Second CAV In Patients With SCLC Who Have Relapsed at Least Three Months After Completion Of First-Line Therapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Randomized, Phase III Trial Comparing CPT-11 (Irinotecan HCL; Camptosar Injection)/ Cisplatin with Etoposide / Cisplatin in Patients with Previously Untreated, Extensive, Small-Cell Lung Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
LUNG CANCER CONTINUED
An Expanded Access Clinical Program with ZD1839 (Iressa™) for Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Trial of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (Taxotere®) in Patients with Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer who have Previously Received Platinum-based Chemotherapy
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
PANCREATIC CANCER
A Double-Blind, Randomized, Mulit-center, Study of Orathecin Capsules Plus Gemcitabine Versus Placebo Capsules Plus Gemcitabine (With an Open-Label Single-Arm Pre-Randomization Phase) in Chemonaive Patients with Non-Resectable Pancreatic Cancer
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
RENAL CANCER
Open-Label, Non-comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma.
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
SUPPORTIVE THERAPY
A Pilot Study to Evaluate the Response Rate of Procrit at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy
Principal Investigator: Haresh Jhangiani, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Randomized, Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib 40 mg BID as Add On Therapy to Opioid Medication in Patients with Chronic Cancer Pain.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
SUPPORTIVE THERAPY CONTINUED
A Randomized Dose-Finding Study of NESP Administered by SQ Injection for the Treatment of Anemia in Subjects with Solid Tumors Receiving Multicycle Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Double Blind, Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor, H376/95 versus Standard Therapy in Patients with Active, Symptomatic DVT with or without PE.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Dose-Finding Study of NESP Administered by SQ Injection for the Treatment of Anemia of Subjects with Chronic Anemia of Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Randomized, Open-Label, Multicenter Study of Subcutaneous and Intravenous Administration of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) for the Treatment of Anemia in Subjects with Non-Myeloid Malignacies Receiving Multicycle Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
A Randomized Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects with Non-Myeloid Malignancies Receiving Multi-Cycle Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Evangeline Reyes, M.D.
Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting in Cancer Patients Undergoing Repeated Cycles of Moderately Emetogenic Chemotherapy
Principal Investigator: Evangeline Reyes, M.D.
A Multi-Center, Open-Label, Long-Term Study of OraVescent® Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients
Principal Investigator: Evangeline Reyes, M.D.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ORAVESCENT® Fentanyl Citrate in Opioid-Tolerant Patients With Cancer and Breakthrough Pain
Principal Investigator: Evangeline Reyes, M.D.